PMC:7113610 / 18942-19130
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 658 | 0-6 | Chemical | denotes | CR3022 | |
| 664 | 164-172 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 665 | 173-182 | Disease | denotes | infection | MESH:D007239 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T197 | 164-172 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T198 | 173-182 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T181 | 7-10 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T182 | 44-45 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T140 | 0-188 | Sentence | denotes | CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]. |
LitCovid-PMC-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T574 | 117-127 | GO:0042571 | denotes | antibodies |
| T575 | 164-172 | SP_7 | denotes | COVID-19 |
| T61832 | 117-127 | GO:0042571 | denotes | antibodies |
| T75491 | 164-172 | SP_7 | denotes | COVID-19 |